Roche’s earnings hit by Genentech acquisition

The Roche group’s net income declined by 22% to CHF 8.5 billion in 2009 as it absorbed the cost of acquiring and integrating Genentech. Group sales, however, rose by 8% and the company proposed a 20% increase in its dividend.

Location